(Q40919677)

24 September 2017

1 reference

title

Therapeutic potential of anti-HIV immunotoxins (English)

1 reference

24 September 2017

Pincus SH

1

1 reference

24 September 2017

publication date

1 December 1996

1 reference

24 September 2017

1 reference

24 September 2017

volume

33

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

1-9

1 reference

Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Immunotoxins: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

CD4-Pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2900995-3

7 January 2021

10.1016/S0166-3542(96)00995-3

Identifiers

DOI

1 reference

24 September 2017

1 reference